Home / Lab Basics / IGF-1

IGF-1: what it is and why growth hormone peptides affect it

What IGF-1 actually does

IGF-1 is a small protein, structurally similar to insulin (hence the name), that circulates in the bloodstream and binds to receptors on almost every tissue. Its primary effect is anabolic: it promotes growth and repair of tissue, particularly muscle, bone, and connective tissue. Most circulating IGF-1 is produced by the liver in response to growth hormone signalling.

The physiological job of IGF-1 is straightforward: when growth hormone tells the liver to produce it, IGF-1 goes out and delivers the signal to the rest of the body that it is time to grow, repair, and invest resources in anabolic processes. Children have much higher IGF-1 levels than adults, because childhood is the main phase of biological growth. Adults maintain lower but nonzero levels throughout life.

The reason IGF-1 is the lab marker of choice for growth-hormone-axis questions is that growth hormone itself is difficult to measure meaningfully. Growth hormone is released from the pituitary in pulses, mostly at night, and a single blood draw during the day usually shows a very low value regardless of what the pituitary is doing overall. IGF-1, by contrast, is produced continuously and has a much longer half-life in blood, which makes it a stable integrated reading of what growth hormone has been doing over the recent past.

The GH/IGF-1 axis in plain language

Three organs. One feedback loop. That is the whole system.

1. The hypothalamus releases growth hormone releasing hormone (GHRH), which tells the pituitary to release growth hormone. It also releases somatostatin, which tells the pituitary to slow down.
2. The pituitary releases growth hormone (GH) into the bloodstream in pulses, mostly at night during deep sleep.
3. The liver picks up the GH signal and produces IGF-1, which goes to the rest of the body and delivers the anabolic effects.

The feedback loop: when IGF-1 is high, it tells the hypothalamus and pituitary to slow down. When IGF-1 is low, the signal to produce more GH goes up. A healthy axis self-regulates to maintain a reasonable set point.

Almost every peptide sold under the “growth hormone” umbrella acts on one of the first two organs. GHRH analogs (like Tesamorelin and Sermorelin) mimic the hypothalamic signal that tells the pituitary to release GH. Ghrelin receptor agonists (like Ipamorelin and Hexarelin) act through a different pathway on the pituitary but with the same downstream effect of prompting GH release. CJC-1295 is a longer-acting GHRH analog. None of these peptides are growth hormone itself. They all work by pushing the pituitary to release more of its own growth hormone, which then goes to the liver, which then produces more IGF-1.

Why IGF-1 is the standard marker for GH-axis peptides

Every peptide acting on the GH axis eventually produces its effect (if it produces one) by increasing growth hormone output, which increases IGF-1 output, which produces the anabolic and metabolic effects users are chasing. If IGF-1 does not move, the peptide is not doing what it is supposed to do, full stop.

That is why clinician-supervised use of Tesamorelin (the FDA-approved GHRH analog) includes baseline IGF-1 and follow-up IGF-1 in the monitoring plan. If a patient on Tesamorelin sees an IGF-1 that has moved meaningfully above baseline, the peptide is doing its job. If the IGF-1 has not moved, either the preparation is not active or the patient is not responding. Either way, the lab answers a question that cannot be answered any other way.

The same logic applies to every other peptide in this class. A peptide that claims GH-axis effects but does not move IGF-1 is not producing GH-axis effects, regardless of how the user feels. This is one of the most important clarifications the lab marker provides: it separates real pharmacological effect from placebo response, and it separates a working preparation from one that is not.

What “normal range” means and why the range is wide

Reference ranges for IGF-1 are given as age-specific and sex-specific. A twenty-year-old’s expected range is very different from a sixty-year-old’s. Within any age bracket, the published reference range covers roughly the middle 95% of apparently healthy individuals, which means it is wide by design.

Two important caveats:

• Wide ranges are normal. A healthy fifty-year-old can have an IGF-1 anywhere across a several-fold range. Different people run at different set points.
• Assay differences matter. Different labs use different IGF-1 assays, and the values are not always directly comparable across labs. When clinicians track IGF-1 over time, they usually prefer the same lab for each draw.

What this means practically: a single IGF-1 number in isolation does not tell you much. The direction and magnitude of change over time, measured consistently, is the useful signal. That is why a clinician focuses on the trajectory, not the single data point.

IGF-1 and cancer risk: why clinicians care

This is the part every GH-axis conversation returns to, and it is worth understanding plainly.

IGF-1 is anabolic. It tells cells to grow. Cells that are already dysregulated (for example, pre-cancerous cells) can respond to that signal the same way healthy cells do. Observational studies have linked elevated IGF-1 levels to increased risk of several cancers, most consistently colorectal and possibly prostate and breast. The association is not new and is not in dispute. What remains less settled is whether pharmacologically raising IGF-1 (through a GH-axis peptide) increases cancer risk to a meaningful degree in adults, or whether the observational associations reflect something else entirely.

What a thoughtful clinician does with this: they want to know your baseline IGF-1, your personal and family cancer history, and, before recommending anything that might push IGF-1 higher, they have an honest conversation about the risk model. For someone with a significant personal or family history, the calculus is different. For someone without, the risk signal is present but smaller. The conversation is not binary, and it does not happen from a blog post.

The relevant framing: growth hormone replacement is prescribed for specific clinical indications (for example, adult growth hormone deficiency or HIV-associated lipodystrophy in the case of Tesamorelin), and the prescribing guidance includes IGF-1 monitoring precisely so that levels do not overshoot. Chasing a high IGF-1 in the absence of a clinical reason is not what the labeled use supports.

Questions to ask your clinician about IGF-1

If IGF-1 is part of your conversation, these are the questions worth walking in with.

1. What is my baseline IGF-1, and how does it compare to the age-specific reference range from the lab that ran it?
2. Given my personal and family history, how do you weight the IGF-1/cancer risk signal in this specific conversation?
3. If we proceed with a GH-axis peptide, what IGF-1 trajectory would you consider “working,” and what trajectory would make you want to step back?
4. How often would you want to recheck IGF-1, and through which lab, to keep the values comparable over time?
5. Are there lifestyle factors (sleep, exercise, body composition, calorie restriction) that you would want me to address first, given their known effect on IGF-1?
6. What would make you recommend pausing or stopping a GH-axis peptide based on lab findings alone?

What to do next

Sources

• Endocrine Society. Clinical practice guidelines on IGF-1 measurement and adult growth hormone deficiency.
• Juul A, et al. Age- and sex-specific reference ranges for IGF-1. Peer-reviewed literature referenced in major assays.
• Renehan AG, et al. Systematic reviews on IGF-1 and cancer incidence, published in The Lancet and related journals.
• FDA prescribing information for Tesamorelin (Egrifta), including IGF-1 monitoring recommendations.
• Clemmons DR. IGF-1 assay performance and inter-laboratory variability, clinical chemistry literature.

Citations are illustrative references for the framing above. None of the content is a substitute for an individual lab interpretation by a licensed clinician.

Related reading